Evidence map›Paper›PMID 39395839›Full record

ArticleJournal for immunotherapy of cancer2024

Cancer-associated foam cells hamper protective T cell immunity and favor tumor progression in human colon carcinogenesis.

Elena Daveri, Barbara Vergani, Luca Lalli, Giulio Ferrero, Elena Casiraghi, Agata Cova, Marta Zorza, Veronica Huber, Manuela Gariboldi, Patrizia Pasanisi and 15 more

Abstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Elena DaveriUnit of Translational Immunology, Department of Experimental Oncology, Fondazione IRCCS, Istituto Nazionale dei Tumori di Milano, Milan, Italy elena.daveri@istitutotumori.mi.it licia.rivoltini@istitutotumori.mi.it.ORCID http://orcid.org/0000-0001-8351-2762
Barbara VerganiSchool of Medicine and Surgery, University of Milano Bicocca, Monza, Italy.
Luca LalliUnit of Translational Immunology, Department of Experimental Oncology, Fondazione IRCCS, Istituto Nazionale dei Tumori di Milano, Milan, Italy.
Giulio FerreroDepartment of Clinical and Biological Sciences, University of Turin, Turin, Italy.
Elena CasiraghiAnacleto Lab, Computer Science Department, University of Milan, Milan, Italy.ORCID http://orcid.org/0000-0003-2024-7572
Agata CovaUnit of Translational Immunology, Department of Experimental Oncology, Fondazione IRCCS, Istituto Nazionale dei Tumori di Milano, Milan, Italy.
Marta ZorzaUnit of Translational Immunology, Department of Experimental Oncology, Fondazione IRCCS, Istituto Nazionale dei Tumori di Milano, Milan, Italy.
Veronica HuberUnit of Translational Immunology, Department of Experimental Oncology, Fondazione IRCCS, Istituto Nazionale dei Tumori di Milano, Milan, Italy.ORCID http://orcid.org/0000-0001-6304-3575
Manuela GariboldiMolecular Epigenomics, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Patrizia PasanisiResearch in Nutrition and Metabolomics, Department of Reaserch, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
Simonetta GuarreraCandiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.
Daniele MorelliLaboratory Medicine Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Flavio ArientiImmunohematology and Trasfusion Medicine Service (SIMT), Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Marco VitellaroUnit of Hereditary Digestive Tract Tumors, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Paola A CorsettoDepartment of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy.
Angela M RizzoDepartment of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy.
Martina StrosciaUnit of Translational Immunology, Department of Experimental Oncology, Fondazione IRCCS, Istituto Nazionale dei Tumori di Milano, Milan, Italy.
Paola FratiUnit of Translational Immunology, Department of Experimental Oncology, Fondazione IRCCS, Istituto Nazionale dei Tumori di Milano, Milan, Italy.
Vincenzo LaganoFirst Division of Pathology, Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Laura CattaneoFirst Division of Pathology, Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Giovanna SabellaFirst Division of Pathology, Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Biagio E LeoneSchool of Medicine and Surgery, University of Milano Bicocca, Monza, Italy.
Massimo MilioneFirst Division of Pathology, Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Luca SorrentinoUnit of Colorectal Surgery, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Licia RivoltiniUnit of Translational Immunology, Department of Experimental Oncology, Fondazione IRCCS, Istituto Nazionale dei Tumori di Milano, Milan, Italy elena.daveri@istitutotumori.mi.it licia.rivoltini@istitutotumori.mi.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundColorectal cancer (CRC) remains a significant healthcare burden worldwide, characterized by a complex interplay between obesity and chronic inflammation. While the relationship between CRC, obesity and altered lipid metabolism is not fully understood, there are evidences suggesting a link between them. In this study, we hypothesized that dysregulated lipid metabolism contributes to local accumulation of foam cells (FC) in CRC, which in turn disrupts antitumor immunosurveillance.

methodsTumor infiltrating FC and CD8

resultsFC (large CD68

conclusionsFC exert immunosuppressive activity through a TGF-β-related pathway, resulting in a CD8-excluded microenvironment and identifying immunosuppressed tumors with worse prognosis in patients with primary CRC. FC association with patient BMI and dyslipidemia might explain the link of CRC with obesity, and offers novel therapeutic and preventive perspectives in this specific clinical setting.

Indexed as

Disease ProgressionAgedCarcinogenesisColonic NeoplasmsFemaleHumansMaleMiddle AgedTumor MicroenvironmentColorectal CancerImmunosuppressionMacrophageTumor microenvironment - TME

Identifiers

PMID39395839
PMCPMC11474856

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.